Ewan Townsend assists clients in the life sciences sector on regulatory and commercial matters. He has experience with a broad range of regulatory issues that arise throughout the medicinal product and medical device life cycle, including research and development, clinical trials, marketing authorisations, manufacturing, distribution, advertising, pricing and reimbursement.

Ewan's work also includes drafting and negotiating commercial agreements for his life sciences clients, such as licence agreements, manufacturing, distribution and supply agreements, clinical trial agreements and service agreements, and advising on the intellectual property and regulatory issues that arise in the context of those transactions.

In addition to his work in private practice, Ewan has spent time in-house with GlaxoSmithKline and Gilead in London, and Novartis in Sydney.

Ewan has a degree in natural sciences from Cambridge University, and studied law at a post graduate level.


  • Novartis on the divestment of its Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo Pharma USA Inc.
  • Novartis on its licensing and supply agreement with Spark Therapeutics for development, registration and commercialization rights outside the US, for one-time gene therapy known as Luxturna.
  • Global pharmaceutical company in negotiating a variety of inter-related agreements with its suppliers and contract manufacturers relating to the development, contract manufacture and supply of an injectable diabetes product.
  • Global pharmaceutical company in negotiating a product transfer and subsequent supply agreements relating to a range of medicated pastilles and nutritional products.
  • Global pharmaceutical company on rebate agreements relating to the supply of its product to health bodies across the UK.
  • Global pharmaceutical company in drafting and implementing a suite of clinical trial agreements for use in its worldwide clinical trials programme.
  • Global pharmaceutical company on deficiencies in its distribution agreements and developing recommendations for restructuring its supply chain.


Life Sciences (UK) 2019 (pdf)
Chambers Global Practice Guide
Frustrated by Brexit?
BioSlice Blog
Revised guidance on implementation of the EU Falsified Medicines Directive
BioSlice Blog
2019 Regulatory Boot Camp
Arnold & Porter's Future Pharma Forum, London, United Kingdom
Legal Aspects of mHealth Solutions
Pharma Licensing Club Germany (PLCD), Dusseldorf


The Legal 500 UK
Pharmaceuticals & Biotechnology (2017-2019)
Intellectual Property (2018-2019)


  • Post-Graduate Diploma in Intellectual Property Law and Practice, Bristol University, 2008
  • Legal Practice Course, BPP Law School, 2005
  • Graduate Diploma in Law, BPP Law School, 2004
  • BA (Hons), Natural Sciences, Cambridge University, 2003
  • England and Wales

Email Disclaimer